Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories
A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.